The ability to sensitively and quantitatively analyze proteins, peptides, small molecules and metabolites is critical to understanding differences between normal and disease states in cells, tissues and organisms. Such analyses typically require sophisticated technical expertise and state-of-the-art instrumentation. The Biopolymers & Proteomics Core (B&P Core) provides Koch Institute researchers with a diverse range of services, with an emphasis on protein/peptide, proteomic and mass spectrometry services, that enable both synthesis and analysis of biological materials. These are technologies that individual researchers usually do not learn, but are essential for modern cancer research, and as such the Core provides access to these techniques. In the current funding period, the B&P Core added new capabilities and modified existing services, including: acquisition of two new hybrid quadrupole-orbitrap MS instruments with funds from Institutional sources to expand proteomics analysis capacity and improve sensitivity; upgraded HPLC with funds from Institutional sources to enable improved fractionation of complex samples and added independent HPLC use; and expanded expertise in HPLC analysis and purification (e.g. small molecule-drug conjugates). Center Member Core use has been strong: 84% of Center Members use the Core, account for 74% of Core service use, and include investigators from all three Research Programs. In the upcoming period, the B&P Core will continue to offer a wide range of state-of-the-art services to support Center Member research programs, and will evaluate emerging capabilities in the context of Center Member needs and interests. A number of new initiatives are planned, including: expansion and enhancement of proteomics capabilities in global and quantitative proteomic analysis, detection of post-translational modifications and identification of binding partner profiling; and improved investigator support for mass spectrometry-related informatics and complex proteomic data analyses. The B&P Core is also committed to maintaining instrumentation at the leading edge, and will continue to closely monitor technological improvements, particularly with regard to LC-MS instrument sensitivity, specificity, operation, and speed. The Core has taken advantage of leasing and vendor consignment programs to provide more frequent instrumentation updates, allowing the Core to pilot new advances and technologies at lower relative cost. In the upcoming funding period, we will conduct a hands-on assessment of Center Member needs with respect to metabolomics capabilities. Funding for any new equipment acquisitions will be solely from Institutional sources. This Shared Resource is essential to the success of the Koch Institute mission and provides exceptional value to the CCSG. The requested CCSG budget for Year 49 is increased by 18.5% over the Core CCSG budget for the current period (Year 48), reflecting increased support for proteomics expertise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014051-49
Application #
9937090
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
49
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02142
McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge et al. (2018) JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest 128:789-804
Richardson, Christopher E R; Cunden, Lisa S; Butty, Vincent L et al. (2018) A Method for Selective Depletion of Zn(II) Ions from Complex Biological Media and Evaluation of Cellular Consequences of Zn(II) Deficiency. J Am Chem Soc 140:2413-2416
Choudhury, Atish D; Werner, Lillian; Francini, Edoardo et al. (2018) Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3:
Chen, Pan-Yu; Muzumdar, Mandar Deepak; Dorans, Kimberly Judith et al. (2018) Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 78:985-1002
Wong, Madeline Y; Chen, Kenny; Antonopoulos, Aristotelis et al. (2018) XBP1s activation can globally remodel N-glycan structure distribution patterns. Proc Natl Acad Sci U S A 115:E10089-E10098
Viswanathan, Srinivas R; Nogueira, Marina F; Buss, Colin G et al. (2018) Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet 50:937-943
Goods, Brittany A; Vahey, Jacqueline M; Steinschneider, Arthur F et al. (2018) Blood handling and leukocyte isolation methods impact the global transcriptome of immune cells. BMC Immunol 19:30
Kaczmarek, James C; Kauffman, Kevin J; Fenton, Owen S et al. (2018) Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells. Nano Lett 18:6449-6454
Perez, Dahlia E; Henle, Andrea M; Amsterdam, Adam et al. (2018) Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology. Pigment Cell Melanoma Res 31:604-613
Wu, Connie; Li, Jiahe; Wang, Wade et al. (2018) Rationally Designed Polycationic Carriers for Potent Polymeric siRNA-Mediated Gene Silencing. ACS Nano 12:6504-6514

Showing the most recent 10 out of 904 publications